

## Summary of Product Characteristics

### 1. NAME OF THE MEDICINAL PRODUCT

Mvabea suspension for injection  
Ebola vaccine (MVA-BN-Filo [recombinant])

### 2. QUALITATIVE AND QUANTITATIVE COMPOSITION

One dose (0.5 mL) contains:  
Modified Vaccinia Ankara Bavarian Nordic Virus\* encoding the:  
*Zaire ebolavirus* (EBOV) Mayinga variant glycoprotein (GP)  
*Sudan ebolavirus* Gulu variant GP  
*Tai Forest ebolavirus* nucleoprotein  
*Marburg marburgvirus* Musoke variant GP

Not less than  $0.7 \times 10^8$  infectious units (Inf.U)

\* Produced in chicken embryo fibroblast cells and by recombinant DNA technology. This product contains genetically modified organisms (GMOs).

This vaccine contains trace residues of gentamicin (see section 4.3). For the full list of excipients, see section 6.1.

### 3. PHARMACEUTICAL FORM

Suspension for injection

Light yellow, clear to milky suspension.

### 4. CLINICAL PARTICULARS

#### 4.1 Therapeutic indications

Mvabea, as part of the Zabdeno, Mvabea vaccine regimen, is indicated for active immunisation for prevention of disease caused by Ebola virus (*Zaire ebolavirus* species) in individuals  $\geq 1$  year of age (see sections 4.4 and 5.1).

The use of the vaccine regimen should be in accordance with official recommendations.

#### 4.2 Posology and method of administration

Mvabea should be administered by a trained healthcare worker.

Mvabea is the second vaccination in the prophylactic 2-dose heterologous Ebola


vaccine regimen which consists of vaccination with Zabdeno followed by a second vaccination with Mvabea given approximately 8 weeks later (see sections 4.4 and 5.1) (refer to the SmPC for Zabdeno).

### Posology

#### **Primary vaccination**

A dose (0.5 mL) of Zabdeno (red cap vial) vaccine should be administered as the first vaccination (refer to the SmPC for Zabdeno).

A dose (0.5 mL) of Mvabea (yellow cap vial) vaccine should be administered as the second vaccination approximately 8 weeks after the first vaccination with Zabdeno.



#### **Booster vaccination with Zabdeno (individuals who previously received the Zabdeno, Mvabea 2-dose primary vaccination regimen)**

Individuals who have previously completed the 2-dose primary vaccination regimen can receive a booster dose of Zabdeno. As a precautionary measure, a Zabdeno booster vaccination is recommended in individuals who are at imminent risk of exposure to Ebola virus and have completed the 2-dose primary vaccination regimen more than 4 months ago (see sections 4.4 and 5.1).

#### **Corrective measures in case of inadvertent administration**

If Mvabea is inadvertently administered as the first vaccination, administration of Zabdeno is recommended as the second vaccination approximately 8 weeks later.

If Zabdeno is inadvertently administered as the first and the second vaccination, additional immunisation with Mvabea is recommended approximately 8 weeks after the second vaccination with Zabdeno.

If Mvabea is inadvertently administered as the first and the second vaccination, additional immunisation with Zabdeno is recommended approximately 8 weeks after the second vaccination with Mvabea.

If the second vaccination (Mvabea) of the regimen has been delayed beyond the recommended 8 weeks after the first vaccination (Zabdeno) of the regimen, the Mvabea vaccine should be administered regardless of the elapsed time from the first vaccination with Zabdeno (see section 5.1).

## **Paediatric population**

### Children aged 1 to 17 years

The posology in children aged 1 to 17 years is the same as in adults (see sections 4.8 and 5.1).

### Infants aged less than 1 year

The safety and efficacy of the 2-dose primary vaccination regimen has not been established in infants aged <1 year.

Clinical data are described in sections 4.8 and 5.1, but no recommendation on a posology can be made.

## **Elderly population**

No dosage adjustment is required in elderly individuals  $\geq 65$  years of age.

## **HIV-infected individuals**

No dosage adjustment is required in HIV-infected individuals with infection controlled through antiretroviral therapy (see section 5.1).

### Method of administration

Mvabea should be administered by the intramuscular (IM) route. The preferred site is the deltoid muscle of the upper arm. In younger children, either the deltoid region of the arm or anterolateral aspect of the thigh are acceptable sites for intramuscular injection.

Do not administer this vaccine intravenously or subcutaneously.

The vaccine should not be mixed in the same syringe with any other vaccines or medicinal products. For precautions to be taken before administering the vaccine, see section 4.4.

For precautions regarding thawing, handling and disposal of the vaccine, see section 6.6.

## **4.3 Contraindications**

Hypersensitivity to the active substance or to any of its excipients listed in section 6.1, or trace residues (chicken or egg protein and gentamicin).

## **4.4 Special warnings and precautions for use**

### Traceability

In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.

### Hypersensitivity

Close observation is recommended following vaccination for the early signs of anaphylaxis or anaphylactoid reactions. As with all injectable vaccines, appropriate medical treatment and supervision should always be readily available in case of rare anaphylactic reactions following the administration of the vaccine. Individuals should be observed by a healthcare professional for at least 15 minutes after vaccination.

### Anxiety-related reactions

Anxiety-related reactions, including vasovagal reactions (syncope), hyperventilation or stress-related reactions may occur in association with vaccination as a psychogenic response to the needle injection. It is important that precautions are in place to avoid injury from fainting.

### Thrombocytopenia and coagulation disorders

The vaccine should be given with caution to individuals with thrombocytopenia or any coagulation disorder because bleeding or bruising may occur following an intramuscular administration in these individuals.

### Concurrent illness

Vaccination should be postponed in individuals suffering from an acute severe febrile illness or acute infection, unless the benefit of immediate vaccination outweighs the potential risks. The presence of a minor infection and/or low-grade fever should not delay vaccination.

### Immunocompromised individuals

Safety and immunogenicity of the Zabdeno, Mvabea vaccine regimen has not been assessed in immunocompromised individuals, including those receiving immunosuppressive therapy.

Immunocompromised individuals may not respond as well as immunocompetent individuals to the Zabdeno, Mvabea vaccine regimen.

### Level of protection

The exact level of protection afforded by the vaccine regimen is unknown.

In the absence of field efficacy data, the protective effect of the vaccine regimen in humans was inferred by the bridging of immunogenicity in humans to immunogenicity and efficacy data obtained in non-human primates (immunobridging) (see section 5.1).

If only one of the vaccines, Zabdeno or Mvabea, is received, the efficacy is expected to be reduced as compared to the 2-dose vaccine regimen.

The vaccine regimen might not protect all individuals against Ebola virus (*Zaire ebolavirus* species) disease, and **does not replace precautions to avoid exposure to Ebola virus**. Vaccinated individuals should adhere to local guidelines and recommendations to prevent or treat exposure to Ebola virus.

The Zabdeno, Mvabea vaccine regimen should not be initiated for post-exposure prophylaxis against Ebola virus.

#### Duration of protection

The duration of protection is unknown. A booster dose of Zabdeno administered at various intervals after completion of a primary series with Zabdeno and Mvabea has been shown to elicit an anamnestic response (see section 5.1). As a precautionary measure, a Zabdeno booster vaccination should be considered for individuals at imminent risk of exposure to Ebola virus, for example healthcare professionals and those living in or visiting areas with an ongoing Ebola virus disease outbreak, who completed the 2-dose primary vaccination regimen more than 4 months ago (see sections 4.2 and 5.1).

#### Protection against Filovirus disease

The vaccine regimen is not intended to prevent diseases caused by Filoviruses other than *Zaire ebolavirus* species.

#### Sodium

This medicinal product contains less than 1 mmol sodium (23 mg) per dose, and is considered to be essentially sodium-free.

### **4.5 Interaction with other medicinal products and other forms of interaction**

The safety, immunogenicity and efficacy of co-administration of Mvabea with other vaccines have not been evaluated, and therefore, co-administration is not recommended.

If Mvabea must be given at the same time as another injectable vaccine(s), then the vaccine(s) should always be administered at different injection sites. Do not mix Mvabea with any other vaccine in the same syringe or vial.

### **4.6 Fertility, pregnancy and lactation**

#### Pregnancy

There are no data from the use of Mvabea in pregnant women.

Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity. Zabdeno and Mvabea vaccine regimens elicited detectable Ebola virus (EBOV) GP-specific maternal antibody titres that were transferred to the fetuses (see section 5.3).

As a precautionary measure, it is preferable to avoid vaccination with Mvabea during pregnancy. Nevertheless, considering the severity of Ebola virus disease, vaccination should not be withheld when there is a clear risk of exposure to Ebola infection.

#### Breast-feeding

It is not known whether Mvabea is excreted in human milk.

A risk to the newborns/infants from breast-feeding by vaccinated mothers cannot be excluded.

As a precautionary measure, it is preferable to avoid vaccination with Mvabea during breast-feeding. Nevertheless, considering the severity of Ebola virus disease, vaccination should not be withheld when there is a clear risk of exposure to Ebola infection.

### Fertility

No data are available on fertility in humans. A reproductive toxicity study in animals with Zabdeno and Mvabea vaccine regimens did not reveal any evidence of impaired female fertility. General toxicity studies have not revealed any effects on male sex organs that would impair male fertility (see section 5.3).

### **4.7 Effects on ability to drive and use machines**

Mvabea has no known effect on the ability to drive and use machines.

### **4.8 Undesirable effects**

#### Summary of the safety profile

The most common local adverse reactions reported in adults who received Mvabea were pain (45%), warmth (20%) and swelling (10%) at the injection site. The most common systemic adverse reactions were fatigue (30%), myalgia (26%) and arthralgia (16%). Most adverse reactions occurred within 7 days following vaccination and were mild to moderate in severity and of short duration (2-3 days).

The most common local adverse reaction reported in children 1 to 17 years of age who received Mvabea was pain (21%) at the injection site. The most common systemic adverse reaction was fatigue (11%). Most adverse reactions occurred within 7 days following vaccination. Most adverse reactions were mild to moderate in severity and of short duration (1-3 days).

Pyrexia was reported more frequently for younger children 1 to 3 years of age (8%) and 4 to 11 years of age (4%) compared to adolescents 12 to 17 years of age (2%) and adults (4%). The frequency of pyrexia in younger children was less than that observed in the placebo control group.

The safety profile of Mvabea in children 1 to 17 years of age was generally similar to that observed in adults.

The safety profile of Mvabea in infants 4 to 11 months of age was generally similar to that observed in children 1 to 17 years of age. The randomised, active-controlled phase of clinical trial EBL2005 enrolled 75 participants in the 2-dose primary vaccination regimen.

#### Tabulated list of adverse reactions

Adverse reactions observed during clinical studies are listed below by the following

frequency categories:  
 very common ( $\geq 1/10$ );  
 common ( $\geq 1/100$  to  $< 1/10$ );  
 uncommon ( $\geq 1/1000$  to  $< 1/100$ ); rare ( $\geq 1/10000$  to  $< 1/1000$ ).

Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.

#### Adults

Table 1 shows the adverse reactions reported from clinical trials in adults.

**Table 1: Adverse Reactions Reported in Adults Following Vaccination with Mvabea**

| System Organ Class  | Frequency   | Adverse reactions  |
|---|-------------|--|
| <i>Gastrointestinal disorders</i>                           | common      | vomiting   |
| <i>Skin and subcutaneous tissue disorders</i>               | uncommon    | pruritus   |
| <i>Musculoskeletal and connective tissue disorders</i>      | very common | myalgia, arthralgia  |
|   |             |  |
| <i>General disorders and administration site conditions</i> | very common | fatigue, injection site pain, injection site swelling, injection site warmth |
|   | common      | injection site pruritus  |
|   | uncommon    | injection site induration, injection site erythema                           |

#### Children 1 to 17 years of age

Table 2 shows the adverse reactions reported from clinical trials in children 1 to 17 years of age.

**Table 2: Adverse Reactions Reported in Children 1 to 17 Years of Age Following Vaccination with Mvabea**

| System Organ Class  | Frequency   | Adverse reactions  |
|---|-------------|--|
| <i>Gastrointestinal disorders</i>                           | common      | vomiting <sup>a</sup>  |
| <i>Musculoskeletal and connective tissue disorders</i>      | common      | myalgia, arthralgia  |
| <i>General disorders and administration site conditions</i> | very common | fatigue, injection site pain   |
|   | common      | pyrexia, chills, injection site pruritus, injection site swelling, injection site erythema |

<sup>a</sup> Vomiting was reported more frequently in children 12-17 years of age compared to 1-4 and 5-11 years of age (externally sponsored trial EBL2004).

#### Infants <1 year of age

In infants 4 to 11 months of age (i.e., outside the age indication) adverse reactions were reported following vaccination with Mvabea (EBL2005). Irritability was more frequently reported (frequency: very common) and additional adverse reactions

reported were (frequency: common): decreased appetite, vomiting, pyrexia and injection site pain.

#### Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.

#### **4.9 Overdose**

No case of overdose has been reported.

### **5. PHARMACOLOGICAL PROPERTIES**

#### **5.1 Pharmacodynamic properties**

Pharmacotherapeutic group: Vaccine, other viral vaccines, ATC code:

#### J07BX02 Mechanism of action

Mvabea is a recombinant, non-replicating in human cells, Modified Vaccinia Ankara - Bavarian Nordic (MVA-BN) vectored multivalent Filovirus vaccine that encodes the *Zaire ebolavirus* Mayinga variant GP, *Sudan ebolavirus* Gulu variant GP, *Tai Forest ebolavirus* nucleoprotein, *Marburg marburgvirus* Musoke variant GP. The EBOV GP encoded by Zabdeno has 100% homology to the one encoded by Mvabea. Following administration, the EBOV GP is expressed locally and stimulates an immune response.

#### Efficacy

In the absence of efficacy data from clinical studies, the efficacy of the 2-dose primary vaccination regimen has been assessed through challenge studies in non-human primates (NHP, *Cynomolgus* macaques, *Macaca fascicularis*), the most relevant animal model for EBOV disease. The 2-dose primary vaccination regimen administered at an interval of 8 weeks was protective down to a first dose of  $2 \times 10^9$  virus particle (VP) of Zabdeno, in combination with  $1 \times 10^8$  Inf.U of Mvabea, in a lethal intramuscular EBOV Kikwit NHP challenge model. Humoral immune responses, as measured by the level of EBOV GP-binding antibodies, were strongly correlated to survival in NHP. Protective effect in humans has been inferred through comparison of EBOV GP-binding antibody concentrations (immunobridging).

#### Clinical immunogenicity

In the absence of efficacy data from clinical studies, the protective effect of the vaccine has been inferred from immunogenicity data. Data from 5 clinical studies conducted in Europe, the United States, and Africa in 764 adults 18 to 50 years of age who had received the 2-dose primary vaccination regimen at the 8-week interval were used in this analysis. Anti-EBOV GP binding antibodies were correlated with a protective effect against a rapidly progressing fully lethal Ebola virus infection in non-



human primates. The human immune responses measured 21 days post-dose 2 were associated with an increase of the predicted survival probability from 0% (i.e., fully lethal) to 53.4% (98.68% CI: 33.8%; 70.9%) using the animal model. Based on this analysis, the Zabdeno, Mvabea vaccine regimen can be anticipated to have a protective effect against EBOV disease in humans. Although the relationship between antibody titre and survival has been studied only in adult NHP, immunobridging performed on paediatric subjects, the elderly and HIV-infected subjects suggests that the potential protective effects for these populations are consistent with the one estimated in adults.

### *Immunogenicity*

Immunogenicity data are presented for a total of 842 adults and 509 children (1 to 17 years of age) who had received the 2-dose primary vaccination regimen in Phase II and III clinical studies: study EBL2001 in the UK and France, studies EBL3002 and EBL3003 in the United States, study EBL2002 in Uganda, Kenya, Burkina Faso and Cote d'Ivoire, and study EBL3001 in Sierra Leone. The concentrations of EBOV GP-specific binding antibodies were measured approximately 3 weeks after completion of the 2-dose primary vaccination regimen. These are presented as geometric mean concentrations (GMC).

Immunogenicity data are also assessed in an externally sponsored clinical study (EBL2004) conducted in Guinea, Liberia, Mali, and Sierra Leone. Data are presented for a total of 338 children (1 to 17 years of age), who had received the 2-dose primary vaccination regimen and who had data available at 28 days post-dose 2 (see Table 4).

Immunogenicity data are also assessed in a Phase II clinical study in Sierra Leone and Guinea (EBL2005) in 74 infants aged 4 to 11 months who had received the 2-dose primary vaccination regimen and who had data available at 21 days post-dose 2 (see Table 5).

### *Immunogenicity data in adults after the 2-dose primary vaccination regimen*

The immune response to the 2-dose primary vaccination regimen given in an 8-week interval was assessed in 5 Phase II and III studies conducted in Europe, Africa and the USA (see Table 3). In all studies, 98% to 100% of study participants mounted a binding antibody response to EBOV GP, defined as more than 2.5-fold increase in binding antibody concentration over baseline value.

**Table 3: EBOV GP-specific Binding Antibody Responses to the Zabdeno, Mvabea 2-dose Vaccine Regimen in Adults (8 week interval): GMC EU/mL (95% CI)**

| <b>Study</b> | <b>Baseline</b>                      | <b>21 days post-dose 2</b>       | <b>6 months post-dose 2</b> | <b>10 months post-dose 2</b>  |
|--------------|--------------------------------------|----------------------------------|-----------------------------|-------------------------------|
| EBL2001      | (N=70)<br><LLOQ<br>(<LLOQ;<br><LLOQ) | (N=69)<br>10131<br>(8554; 11999) | -                           | (N=50)<br>1205<br>(971; 1497) |
| EBL2002      | (N=134)<br>39<br>(<LLOQ; 48)         | (N=136)<br>7518<br>(6468; 8740)  | -                           | (N=133)<br>342<br>(291; 401)  |
| EBL3001      | (N=231)                              | (N=224)                          |                             | (N=199)                       |

|         |                                       |                                   |                                 |                   |
|---------|---------------------------------------|-----------------------------------|---------------------------------|-------------------|
|         | 68<br>(56; 81)                        | 3976<br>(3517; 4495)              | -                               | 268<br>(234; 307) |
| EBL3002 | (N=140)<br><LLOQ<br>(<LLOQ;<br><LLOQ) | (N=135)<br>11054<br>(9673; 12633) | (N=131)<br>1263<br>(1100; 1450) | -                 |
| EBL3003 | (N=258)<br><LLOQ<br>(<LLOQ;<br><LLOQ) | (N=254)<br>11052<br>(9959; 12265) | (N=244)<br>1151<br>(1024; 1294) | -                 |

Data shown for vaccinated participants who received the 2-dose vaccine regimen in the Per Protocol Analysis Set. EU = ELISA Units  
CI = Confidence interval  
N = Number of participants  
with data LLOQ = Lower limit of quantification

The interval between doses in these studies was 8 weeks +/- 3 days. While the immunogenicity of vaccine regimens with a longer interval between doses up to 69 weeks (483 days) was similar, vaccine regimens with an interval of 4 weeks were less immunogenic.

Following the 2-dose primary vaccination regimen with an 8-week interval, GMCs EU/mL (95% CI) of 5283 (4094; 6817) were observed in HIV-infected adults on antiretroviral therapy, with CD4+ cells >350 cells/microlitre and no signs of immunosuppression (N=59).

*Immunogenicity data in children (1 to 17 years of age) after the 2-dose primary vaccination regimen* The immune response to the 2-dose primary vaccination regimen given in an 8-week interval was assessed in children (1 to 17 years of age) in three studies conducted in Africa (see Table 4). In the three studies, 98% to 100% of study participants mounted a binding antibody response to EBOV GP. Immune responses in children were higher than those observed in adults in the same studies.

**Table 4: EBOV GP-specific Binding Antibody Responses to the Zabdeno, Mvabea 2-dose Vaccine Regimen in Children 1 to 17 years of age (8 week interval): GMC EU/mL (95% CI)**

| Age        | Study   | Baseline                           | 21 days post-dose 2                 | 6 months post-dose 2         | 10 months post-dose 2         |
|------------|---------|------------------------------------|-------------------------------------|------------------------------|-------------------------------|
| 1-3 years  | EBL3001 | (N=123)<br><LLOQ<br>(<LLOQ; <LLOQ) | (N=124)<br>22568<br>(18426; 27642)  | (N=122)<br>713<br>(598; 849) | (N=120)<br>750<br>(629; 894)  |
| 1-4 years  | EBL2004 | (N=105)<br><LLOQ<br>(<LLOQ; <LLOQ) | (N=108)*<br>25111<br>(21332; 29559) | -                            | (N=28)<br>1139<br>(905; 1432) |
| 4-11 years | EBL2002 | (N=52)<br><LLOQ<br>(<LLOQ; <LLOQ)  | (N=53)<br>17388<br>(12973; 23306)   | (N=53)<br>715<br>(602; 851)  | (N=54)<br>637<br>(529; 767)   |
|            | EBL3001 | (N=130)<br>62<br>(49; 78)          | (N=124)<br>10212<br>(8419; 12388)   | (N=126)<br>442<br>(377; 518) | (N=123)<br>436<br>(375; 506)  |
| 5-11 years | EBL2004 | (N=109)                            | (N=105)*                            |                              | (N=33)                        |

|                        |         |                      |                            |                   |                   |
|------------------------|---------|----------------------|----------------------------|-------------------|-------------------|
|                        |         | <LLOQ<br>(<LLOQ; 40) | 15797<br>(13289;<br>18778) | -                 | 739<br>(585; 933) |
| <b>12-17<br/>years</b> | EBL2002 | (N=53)               | (N=53)                     | (N=41)            | (N=52)            |
|                        |         | <LLOQ<br>(<LLOQ; 37) | 13532<br>(10732;<br>17061) | 577<br>(454; 734) | 541<br>(433; 678) |
|                        | EBL3001 | (N=142)              | (N=134)                    | (N=135)           | (N=132)           |
|                        |         | 65<br>(52; 81)       | 9929<br>(8172; 12064)      | 469<br>(397; 554) | 386<br>(326; 457) |
| EBL2004                | (N=127) | (N=125)*             | -                          | (N=63)            |                   |
|                        |         | 49<br>(39; 62)       | 12279<br>(10432;<br>14452) |                   | 731<br>(589; 907) |

Data shown for vaccinated participants who received the 2-dose vaccine regimen in the Per Protocol Analysis Set.

\* 28 days post-

dose 2 EU =

ELISA Units

CI = Confidence interval

N = Number of participants

with data LLOQ = Lower

limit of quantification

*Immunogenicity data in infants (4 to 11 months of age) after the 2-dose primary vaccination regimen*

The immune response to the 2-dose primary vaccination regimen given in an 8-week interval was also assessed in infants (4 to 11 months of age) in a clinical study (EBL2005) (see Table 5). In this study, 100% of study participants mounted a binding antibody response to EBOV GP, 21 days post-dose 2.

**Table 5: EBOV GP-specific Binding Antibody Responses to the Zabdeno, Mvabea 2-dose Vaccine Regimen in Infants 4 to 11 months of age (8 week interval): GMC EU/mL (95% CI)**

| Age                    | Study   | Baseline                | 21 days post-dose 2     | 10 months post-dose 2 |
|------------------------|---------|-------------------------|-------------------------|-----------------------|
| <b>4-11<br/>months</b> | EBL2005 | (N=74)                  | (N=74)                  | (N=72)                |
|                        |         | <LLOQ<br>(<LLOQ; <LLOQ) | 24309<br>(19695; 30005) | 1466<br>(1090; 1971)  |

Data shown for vaccinated participants who received the 2-dose vaccine regimen in the Per Protocol Analysis Set. EU = ELISA Units

CI = Confidence interval

N = Number of participants

with data LLOQ = Lower limit

of quantification

*Immunogenicity data in adults after Zabdeno booster vaccination*

The immune response to a booster vaccination of Zabdeno administered 1 or 2 years after the primary vaccination regimen was evaluated in 2 clinical studies (see Table 6). Booster vaccination resulted in the rapid activation of an anamnestic response, with a 40- to 56-fold increase in antibody concentrations within 7 days.

The magnitude of the response in terms of fold-increase and post-booster GMC was similar irrespective of the time since primary vaccination (1 or 2 years).

**Table 6: EBOV GP-specific Binding Antibody Responses to Zabdeno Booster Vaccination in Adults: GMC EU/mL (95% CI)**

| Study                | Pre-booster                 | 7 days post-booster                   | 21 days post-booster                  | 1 year post-booster                |
|----------------------|-----------------------------|---------------------------------------|---------------------------------------|------------------------------------|
| EBL2002 <sup>a</sup> | (N=39)<br>366<br>(273; 491) | (N=39)<br>2041<br>6<br>(15432; 27009) | (N=39)<br>4164<br>3<br>(32045; 54116) | (N=37)<br>438<br>3<br>(2969; 6470) |
| EBL3001 <sup>b</sup> | (N=29)<br>274<br>(193; 387) | (N=25)<br>1116<br>6<br>(5881; 21201)  | (N=29)<br>3041<br>1<br>(21972; 42091) | (N=26)<br>323<br>7<br>(2305; 4547) |

<sup>a</sup> booster vaccination administered 1 year after primary vaccination

<sup>b</sup> booster vaccination administered 2 years after primary vaccination

Data shown for vaccinated participants who received the booster

vaccination in the Per Protocol Analysis Set. EU = ELISA Units

CI = Confidence interval

N = Number of participants with data

*Immunogenicity data in children 1 to 11 years of age (at time of 2-dose primary vaccination) after Zabdeno booster vaccination*

The immune response to a booster vaccination of Zabdeno administered more than 3 years after initial vaccination was evaluated in a clinical study (EBL2011) (see Table 7). Booster vaccination resulted in the rapid activation of an anamnestic response with fold increases from pre-booster antibody concentrations of 32-fold in children aged 1 to 3 years and 63-fold in children aged 4 to 11 years. At 21 days post-booster, fold increases in antibody concentrations from pre-booster concentrations were 76-fold in children aged 1 to 3 years and 137-fold in children aged 4 to 11 years.

**Table 7: EBOV GP-specific Binding Antibody Responses to Zabdeno Booster Vaccination in Children 1 to 11 years of age: GMC EU/mL (95% CI)**

| Study   | Pre-booster                 | 7 days post-booster               | 21 days post-booster              |
|---------|-----------------------------|-----------------------------------|-----------------------------------|
| EBL2011 | (N=49)<br>640<br>(461; 888) | (N=50)<br>28561<br>(20255; 40272) | (N=49)<br>64690<br>(48356; 86541) |

Data shown for vaccinated participants (children 1 to 11 years of age at time of 2-dose primary vaccination) who received the booster vaccination (administered >3

years after primary vaccination) in the Per Protocol Analysis Set.

EU = ELISA Units

CI = Confidence interval


N = Number of participants with data

### *Long term persistence of antibodies in adults*

Three weeks after completion of the 2-dose primary vaccination regimen, the immune response (GMC) reaches its peak (“A” in figure 1 below). After the peak the response declines by 6 months and remains stable at least 1 year post-dose 1 (Table 3). As illustrated by the data on 43 adults in study EBL3001, the response remains stable also at two years post-dose 1 (latest time point available) (“B” in figure 1 below). After administration of a booster dose of Zabdeno, a rapid anamnestic response is observed within 7 days. The highest binding antibody concentrations are observed 21 days

post-booster dose (“C” in figure 1 below), followed by a decline in antibody concentrations. At 1 year post-booster dose, GMCs were higher than before administration of the booster dose (“D” in figure 1 below).

**Figure 1. EBOV GP-specific Binding Antibody Responses after the Zabdeno, Mvabea 2-dose vaccine regimen and Zabdeno booster vaccination 2 years after the primary vaccination regimen in adults in study EBL3001<sup>a</sup>; GMC (95% CI)**



<sup>a</sup> The analysis is based on the per protocol analysis set.

The error bars represent the Geometric Mean Concentration and its 95% confidence interval.

The European Medicines Agency has deferred the obligation to submit the results of

studies with Mvabea for the prevention of Ebola virus disease in one or more subsets of the paediatric population (see section 4.2 for information on paediatric use).

This vaccine has been authorised under 'exceptional circumstances'. This means that for scientific reasons it has been impossible to get complete information on this vaccine. The European Medicines Agency will review any new information which may become available every year and this SmPC will be updated as necessary.

## **5.2 Pharmacokinetic properties**

Not applicable.

## **5.3 Preclinical safety data**

Non-clinical data revealed no special hazard for humans based on repeated dose toxicity and local tolerance studies, and a reproductive toxicity study in rabbits.

### General (repeated dose) toxicity studies, including local tolerance

Vaccination of rabbits with various Zabdeno and Mvabea vaccine regimens was well tolerated when administered intramuscularly at full human dose levels. The vaccine-related findings (reflected by inflammatory changes at the injection site, increases in fibrinogen, C-reactive protein and globulin, and microscopic findings of increased lymphoid cellularity and/or germinal centres in the draining lymph nodes and spleen) were noted to be recovering 2 weeks after the last vaccination, and reflect a normal, physiological response associated with vaccination. There were no effects noted that were considered to be adverse.

### Fertility/Reproductive and Developmental Toxicity

Biodistribution studies conducted in the rabbit did not show distribution of the MVA-BN vector to the gonads (testes, ovaries) following IM injection.

The general (repeated dose) toxicity studies with Zabdeno and Mvabea vaccine regimens have not revealed any effects on male sex organs that would impair male fertility. In addition, the general and/or reproductive toxicity studies did not reveal any evidence of impaired female fertility. In a reproductive toxicity study, Zabdeno and Mvabea vaccine regimens did not induce maternal or developmental toxicity following maternal exposure during the pre-mating and gestation period. In this study, the vaccine regimens elicited detectable EBOV GP-specific maternal antibody titres that were transferred to the foetuses.

## **6. PHARMACEUTICAL PARTICULARS**

### **6.1 List of excipients**

Sodium chloride  
Trometamol  
Water for injections  
Hydrochloric acid (for pH adjustment)

## **6.2 Incompatibilities**

In the absence of compatibility studies, Mvabea must not be mixed with other medicinal products.

## **6.3 Shelf life**

4 years at -85°C to -55°C

## **6.4 Special precautions for storage**

Transport frozen at -25°C to -15°C. Upon receipt, the product can be stored as indicated below:

Store in a freezer at -85°C to -55°C at the distributor in case of stockpiling. The expiry date for storage at -85°C to -55°C is printed on the vial and outer carton after EXP.

The vaccine can also be stored by the distributor or end user in a freezer at -25°C to -15°C for a single period of up to 7 months. Upon removal from the -85°C to -55°C freezer, the new expiry date must be written by the distributor or end user on the outer carton and the vaccine should be used or discarded at the end of the 7 months. This new expiry date should not exceed the original expiry date (EXP). The original expiry date should be made unreadable.

The vaccine can also be stored by the distributor or end user in a refrigerator at 2°C to 8°C for a single period of up to 1 month. Upon moving the product to 2°C to 8°C storage, the discard date must be written by the distributor or end user on the outer carton and the vaccine should be used or discarded at the end of the 1 month period. This discard date should not exceed the original expiry date (EXP), or the new expiry date assigned for the -25°C to -15°C storage condition. The original expiry date and/or the new expiry date assigned for the -25°C to -15°C storage condition should be made unreadable.

Once thawed, the vaccine cannot be refrozen.

The vial must be kept in the original package in order to protect from light and to track the expiry or discard date for the different storage conditions.

## **6.5 Nature and contents of container**

0.5 mL suspension in a single-dose Type I glass vial with a rubber stopper (chlorobutyl with fluoropolymer coated surface), aluminium crimp and yellow plastic cap.

Pack size of 20 single-dose vials.

## **6.6 Special precautions for disposal and other handling**

Mvabea is a light yellow, clear to milky suspension. The vaccine should be inspected visually for particulate matter and discolouration prior to administration. The vial should be inspected visually for cracks or any abnormalities, such as evidence of

tampering prior to administration. If any of these should exist, do not administer the vaccine.

Once the vaccine has been removed from the freezer and thawed, use immediately or store in a refrigerator at 2°C to 8°C (see section 6.4). Once removed from the refrigerator for administration, it should be used immediately.

Gently mix the contents of the vial by swirling for 10 seconds. Do not shake. Use a sterile needle and sterile syringe to extract the entire contents from the vial for administration.

Use a separate sterile needle and syringe for each individual. It is not necessary to change needles between drawing up the vaccine from a vial and injecting it into a recipient, unless the needle has been damaged or contaminated. Any remaining content in the vial should be discarded.

Any unused medicinal product or waste material should be disposed of in accordance to local requirements. Potential spills should be disinfected with agents with viricidal activity against vaccinia virus.

## **7. MARKET AUTHORIZATION HOLDER**

Janssen-Cilag International NV  
Turnhoutseweg 30  
B-2340 Beerse  
Belgium